ALKERMES, INC. for ALKERMES, INC.

Medicare/Medicaid MMM

Patient access and maintain six protected class status of medicines to treat serious mental illness under Medicare Part D; Inflation Reduction Act of 2022 implementation; Medicaid Drug Rebate Program proposed rule Misclassification of Drugs, Program Administration and Program Integrity Updates Under the Medicaid Drug Rebate Program

Contacted: HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); SENATE; Health & Human Services, Dept of (HHS)

Health Issues HCR

Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 2163/S. 464 the Safe Step Act; Policies impacting pharmaceutical development, reimbursement, and patient access and cost; Awareness of need for transparency and patient access within the 340B program; H.R. 2882 Further Consolidated Appropriations Act, 2024; Labor, Health and Human Services, Education Appropriations, 2025; Commerce, Justice, Science, and Related Agencies Appropriations, 2025; H.R.8580 - Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2025; PDUFA Implementation and efficiency improvements at the FDA;

Contacted: SENATE; Health & Human Services, Dept of (HHS); Office of Natl Drug Control Policy (NDCP); HOUSE OF REPRESENTATIVES; Substance Abuse & Mental Health Services Administration (SAMHSA); Executive Office of the President (EOP); Natl Institutes of Health (NIH)

Bills named: H.R. 2882 (118th), H.R. 8580 (118th), S. 464 (118th), H.R. 2163 (118th)

Alcohol and Drug Abuse ALC

Expand funding and flexibility to address all substance use disorders;

Contacted: SENATE; Veterans Affairs, Dept of (VA); Substance Abuse & Mental Health Services Administration (SAMHSA); Health & Human Services, Dept of (HHS); Executive Office of the President (EOP); HOUSE OF REPRESENTATIVES; Justice, Dept of (DOJ)